InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,975.39
(
1.10%
)
Post# of 252428
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: poorgradstudent post# 186416

Wednesday, 01/21/2015 9:49:37 PM

Wednesday, January 21, 2015 9:49:37 PM

Post# of 252428
Only after understanding the targets better, and their clinical profiles better do they start to focus on isoforms or narrower targets. This could be a case in the future. Almost all examples you gave started with pan-inhibition at first.

GS9450 is a caspase inhibitor. The good news is GILD tested it in a ph2 study for NASH with positive marker data:

http://www.reuters.com/article/2010/04/16/gilead-liver-idUSN1524808920100416

The bad news is the drug was discontinued after safety issue in a ph2 HCV trial:

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1414682
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up